[1] Martelli M, Ferreri A J, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol, 2013, 87: 146-171.
[2] Couronne L, Bachy E, Roulland S, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol, 2018, 29: 92-100.
[3] Kuna L, Jakab J, Smolic R, et al. HCV extrahepatic manifestations. J Clin Transl Hepatol, 2019, 7: 172-182.
[4] Dlouhy I, Torrente M A, Lens S, et al. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Ann Hematol, 2017, 96: 405-410.
[5] Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis. Liver Int, 2019, 39:1292-1306.
[6] Hosry J, Mahale P, Turturro F, et al. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer, 2016, 139: 2519-2528.
[7] Pol S, Vallet-Pichard A, Hermine O. Extrahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol, 2018, 15: 283-290.
[8] Khaled H, Abu-Taleb F, Haggag R. Hepatitis C virus and non-Hodgkin's lymphomas: a minireview. J Adv Res, 2017, 8: 131-137.
[9] Pellicelli A, Giannelli V, Zoli V, et al. Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma. Clin Exp Hepatol, 2018, 4: 197-200.
[10] Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin's lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol, 2016, 8: 107-116.
[11] Vannata B, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program, 2014, 2014: 590-598. |
